Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson's disease: a clinical survey in PD patients and age‐matched healthy volunteers

Ferreira, Joaquim J.; Desboeuf, Karine; Galitzky, Monique; Thalamas, Claire; Brefel‐Courbon, Christine; Fabre, Nelly; Senard, Jean‐Michel; Montastruc, J. L.; Sampaio, Cristina; Rascol, Olivier

doi:10.1111/j.1468-1331.2006.01262.x

Cited by 76 publications

(54 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding daytime sleepiness, our cohort had a mean (SD) ESS score of 7.4 (4.5), while Mahale et al [31] reported ESS scores (mean ± SD) of 8.3 ± 3.5 and 6.8 ± 3.5 for the OOPD and YOPD, respectively. Our clinical data was in concordance with those reported by Verbaan et al [24] and Ferreira et al [32]. In this regard, Verbaan et al [24] reported the nighttime sleep problems and daytime sleepiness in PD patients with the mean age of PD onset (SD) of 50.6 (12.0) years and mean (SD) age of 61.1 (11.5) years old.…”

Section: Discussion/conclusionsupporting

confidence: 82%

“…Compared to the control group, a significantly greater proportion of patients had EDS (43 vs. 10%), and excessive night-time sleep problem (27 vs. 9%) [24]. Results from a study by Ferreira et al [32] also reported sleep disruption, daytime somnolence and SA among PD patients in their clinical survey. In the study, the mean age (SD) and the disease duration of their patients were 65 (10) years old and 10.0 (5.9) years, respectively, suggesting that the age of PD onset was approximately 55 years old.…”

Section: Discussion/conclusionmentioning

confidence: 63%

See 1 more Smart Citation

Association between Sleep Disturbances and Daytime Somnolence in Parkinson’s Disease

2018

View full text Add to dashboard Cite

Background: Sleep disturbance is a common problem among patients with Parkinson’s disease (PD). Objectives: To investigate the prevalence of daytime somnolence and night-time sleep disturbances; to characterise the night-time sleep disturbance in patients with daytime somnolence; and to determine the correlation between daytime somnolence and night-time sleep disturbances. Methods: One hundred and sixty patients with PD were included in the study. Each patient completed the Thai version of the Epworth Sleepiness Scale (ESS) questionnaire to evaluate excessive daytime sleepiness (EDS), and the PD Sleep Scale version-2 (PDSS-2) questionnaire to evaluate night-time sleep disturbance. Subjective sleep information and details about the presence or absence of sleep attack (SA) were also obtained from the patients. Results: The types of daytime somnolence found in this study were EDS, SA, and combination of EDS and SA (EDS + SA) with the prevalence rates of 22.5, 3.1 and 6.3%, respectively. The prevalence of night-time sleep disturbance was 46.9%. The most common nocturnal disturbance (82.5%) was “get up at night to pass urine”. There was a significant positive correlation between the ESS score and PDSS-2 total score with a correlation coefficient of 0.16 (p = 0.043). Patients with “EDS + SA” were the most affected by nocturnal disturbances, as they represented the largest group among those patients with night-time disturbances and had the highest PDSS-2 total score (p < 0.05). Conclusion: There are differences in nocturnal sleep disturbances among PD patients with different types of daytime somnolence. The significant positive correlation between the ESS and the PDSS-2 total scores suggests that night-time sleep disturbance may influence daytime somnolence.

show abstract

Section: Discussion/conclusionsupporting

confidence: 82%

Section: Discussion/conclusionmentioning

confidence: 63%

Association between Sleep Disturbances and Daytime Somnolence in Parkinson’s Disease

2018

View full text Add to dashboard Cite

show abstract

“…Varying estimates have been reported, ranging from 15% to 75%. 370,374,[940][941][942][943][944][945][946] The wide variation in the prevalence of EDS in patients with PD is probably due to the different populations studied and the tools used to assess the presence of EDS. The most commonly used tools are the ESS, Scales for Outcomes in PD (SCOPA-SLEEP), PDSS, MSLT, and PSG.…”

mentioning

confidence: 99%

The scientific and clinical basis for the treatment of Parkinson disease (2009)

Olanow¹,

Stern²,

Sethi³

2009

Neurology

773

658

View full text Add to dashboard Cite

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many as 1-2% of persons aged 60 years and older. With the aging of the population, the frequency of PD is expected to increase dramatically in the coming decades. Current therapy is largely based on a dopamine replacement strategy, primarily using the dopamine precursor levodopa. However, chronic treatment is associated with the development of motor complications, and the disease is inexorably progressive. Further, advancing disease is associated with the emergence of features such as freezing, falling, and dementia which are not adequately controlled with dopaminergic therapies. Indeed, it is now appreciated that these nondopaminergic features are common and the major source of disability for patients with advanced disease. Many different therapeutic agents and treatment strategies have been evaluated over the past several years to try and address these unmet medical needs, and many promising approaches are currently being tested in the laboratory and in the clinic. As a result, there are now many new therapies and strategic approaches available for the treatment of the different stages of PD, with which the treating physician must be familiar in order to provide patients with optimal care. This monograph provides an overview of the management of PD patients, with an emphasis on pathophysiology, and the results of recent clinical trials. It is intended to provide physicians with an understanding of the different treatment options that are available for managing the different stages of the disease and the scientific rationale of the different approaches. 1 PD is the second most common neurodegenerative disorder, with an average age at onset of about 60 years. An estimated 5 million people throughout the world have PD, with 1 million individuals each in the United States and in Europe with the disorder. PD affects approximately 0.3% of the population and 1% to 2% of those older than 60 years.2 With the aging of the population and the substantial increase in the number of at-risk individuals older than 60 years, it is anticipated that the prevalence of PD will increase dramatically in the coming decades.

show abstract

“…For example, impulse-control disorders are seldom reported in clinical trials [5] but were found to affect about 13% of patients in a recent cross-sectional study [23]. Similarly, somnolence has been reported by 2.5 or 17% of patients on ergolinic or nonergolinic dopamine agonists in clinical trials [23] but has been found to affect 33-48% of patients recruited in recent crosssectional studies where somnolence was systematically explored [24,25]. Thus, clinical trials of antiparkinsonian drugs should always include systematic measures of somnolence and impulse-control disorders, such as Epworth Sleepiness Scale [26] and the Modified Minnesota Impulsive Disorders Interview [27].…”

Section: Discussionmentioning

confidence: 94%